文献速递胸部肿瘤放疗放疗物理与技术

早期肺癌立体定向放疗后总生存列线图的开发与外部验证

Development and external validation of a nomogram to predict overall survival following stereotactic body radiotherapy for early-stage lung cancer.
PubMed 文献 · Radiat Oncol · 2020-04-22

研究基于587例接受生物有效剂量>100 Gy10的早期非小细胞肺癌患者建立预测6个月、1年、3年和5年总生存的列线图,并在124例中央型肿瘤患者中外部验证。列线图含年龄、性别、KPS、可手术性、Charlson合并症指数和肿瘤直径六个因素,内部校正C指数0.64,外部验证C指数0.62。

要点

  • 列线图基于年龄、性别、KPS、可手术性、CCI和肿瘤直径六个预后因素。
  • 内部校正C指数为0.64,外部验证队列C指数为0.62,区分能力中等。
  • 校准曲线斜率为0.77,预测生存与Kaplan-Meier估计存在一定偏差。

核心结论

  • 建立的列线图可为接受SBRT的早期肺癌患者提供个体化生存预测,可能辅助治疗决策。

研究设计与样本

  • 研究纳入587例接受生物有效剂量>100 Gy10的早期NSCLC患者,用Cox比例风险模型构建列线图,内部采用bootstrap抽样验证,外部在124例接受SBRT的中央型肿瘤NSCLC患者中验证。

主要发现

  • 列线图预测6个月、1年、3年和5年总生存,基于年龄、性别、KPS、可手术性、CCI和肿瘤直径六个因素。
  • 内部校正C指数为0.64,外部验证C指数为0.62。
  • 校准曲线斜率为0.77。

关键数值与推荐

  • 纳入标准为接受SBRT且生物有效剂量>100 Gy10的早期NSCLC患者。
  • 区分能力用C指数衡量,预测准确性用校准斜率和校准图评估。

临床怎么用

  • 该列线图可用于接受SBRT的早期肺癌患者的个体化生存预测,辅助患者和临床医生进行治疗决策。

局限性

  • 外部验证队列为中央型肿瘤患者,与开发队列的外周型早期疾病不同。
  • 列线图区分能力中等,内部校正C指数0.64、外部验证C指数0.62。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prognostication tools for early-stage non-small cell lung cancer (NSCLC) patients treated with stereotactic body radiotherapy (SBRT) are currently lacking. The purpose of this study was to develop and externally validate a nomogram to predict overall survival in individual patients with peripheral early-stage disease. METHODS: A total of 587 NSCLC patients treated with biologically effective dose > 100 Gy10 were eligible. A Cox proportional hazards model was used to build a nomogram to predict 6-month, 1-year, 3-year and 5-year overall survival. Internal validation was performed using bootstrap sampling. External validation was performed in a separate cohort of 124 NSCLC patients with central tumors treated with SBRT. Discriminatory ability was measured by the concordance index (C-index) while predictive accuracy was assessed with calibration slope and plots. RESULTS: The resulting nomogram was based on six prognostic factors: age, sex, Karnofsky Performance Status, operability, Charlson Comorbidity Index, and tumor diameter. The slope of the calibration curve for nomogram-predicted versus Kaplan-Meier-estimated overall survival was 0.77. The C-index of the nomogram (corrected for optimism) was moderate at 0.64. In the external validation cohort, the model yielded a C-index of 0.62. CONCLUSIONS: We established and validated a nomogram which can provide individual survival predictions for patients with early stage lung cancer treated with SBRT. The nomogram may assist patients and clinicians with treatment decision-making.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Baker S, Bakunina K, Duijm M, et al. Development and external validation of a nomogram to predict overall survival following stereotactic body radiotherapy for early-stage lung cancer. Radiat Oncol. 2020. PMID: 32321553. doi:10.1186/s13014-020-01537-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。